Industrializing IO Therapeutic Discovery Platforms: Multispecifics, Engineered TCRs and CARs

April 8, 2019

Presented at Keystone - Antibodies as Drugs, Breckenridge, CO, USA

We present two aspects of our work in streamlining next-gen protein therapeutic discovery platforms: First, we address the need for more extensive exploration of the design space for bi/multi-targeting by automating the production and screening of very large panels of bi/multispecific candidate molecules. Second, we address the need to optimize highly complex processes and capture data during CAR-T cell design, production and evaluation, across various donor cell lines and tumor cell lines, using in vitro assays and xenograft tumor models.

Back to list